

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098494501US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: April 1, 2002

Signature: Staci Harris

(Staci Harris)

10/089700 #3  
JC13 Rec'd PCT/PTO 01 APR 2002

Docket No.: HO-P02416US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Robert Anderson et al.

Application No.: UNKNOWN

Group Art Unit: N/A

Filed: April 1, 2002

Examiner: Not Yet Assigned

For: DIAGNOSIS OF COELIAC DISEASE  
USING A GLIADIN EPITOPE

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith. A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Application No.: UNKNOWN

10/089700  
JC Rec'd PCT/PTO 01 APR 2002  
Docket No.: HO-P02416US0

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. 10203581.

Dated: April 1, 2002

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5407

(713) 651-5246 (Fax)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>C mplete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	UNKNOWN
				Filing Date	April 1, 2002
				First Named Inventor	Robert Anderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	HO-P02416US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A	EP0-0 905 518 A1	03-31-1999	Koning, Frits		

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B	ARENTZ-HANSEN, Helene; The Intestinal T Cell Response to $\alpha$ -Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase; <i>J. Exp. Med.</i> Volume 191, No. 4, 2-2000 603-612.	
	C	ANDERSON, Robert et al.; <i>in vivo</i> antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope; <i>Nature Medicine</i> Vol. 6, No. 3, March 2000; 337-342.	
	D	UHLIG, H. et al., Role of Tissue Transglutaminase in Gliadin Binding to Reticular Extracellular Matrix and Relation to Coeliac Disease Autoantibodies; <i>Autoimmunity</i> , Vol. 28, pp. 185-195.	
	E	Database SwissProt Online! ID: GDA4-Wheat ACC:P04724, 13 August 1987 (Abstract)	
	F	OKITA, T. et al., Evolution and Heterogeneity of the $\alpha$ -1 $\beta$ -type and $\gamma$ -type Gliadin DNA Sequences; <i>The Journal of Biological Chemistry</i> ; Vol. 260, No. 13, July 5, 1985; pp. 8203-8213.	
	G	GODKIN, A.S. et al. Identification of a Coeliac Disease-Specific T Cell Epitope from A-Gliadin; <i>Gut</i> ; Vol. 44, suppl. 1, page A72, April 1999.	
	H	TRONCONE, R. et al. Cytokines produced by Gliadin-Specific T Cell Clones from the Coeliac Mucosa; <i>Gastroenterology</i> , Vol. 110, No. 4, p. A103, April 1996.	
	I	VAN DE WAL, Y et al., Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin; <i>Proc. Natl. Acad. Sci.</i> Vol. 95, pp. 10050-10054, August 1998; <i>Immunology</i> .	
	J	O'KEEFFE, J. et al. T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC); <i>Clin Exp. Immunol</i> ; 1999; 117:269-276.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.